Fisher, Matthew C. http://orcid.org/0000-0002-1862-6402
Denning, David W. http://orcid.org/0000-0001-5626-2251
Article History
First Online: 6 February 2023
Competing interests
: M.C.F. has been paid for talks on behalf of Gilead. D.W.D. and family hold Founder shares in F2G Ltd, a University of Manchester spin-out antifungal discovery company that is developing Olorofim, and share options in TFF Pharma. D.W.D. acts or has recently acted as a consultant to Pulmatrix, Pulmocide, Biosergen, TFF Pharmaceuticals, Pfizer, Omega, Novacyt, Rostra Therapeutics, MucPharm and Cipla. D.W.D. sat on the Data and Safety Monitoring Board for a SARS-CoV-2 vaccine trial and chairs a Data Review Committee for Pulmocide. In the past 3 years, D.W.D. has been paid for talks on behalf of Hikma, Gilead, BioRad, Basilea, Mylan and Pfizer. D.W.D. is a longstanding member of the Infectious Disease Society of America Aspergillosis Guidelines group, the European Society for Clinical Microbiology and Infectious Diseases Aspergillosis Guidelines group, and recently joined the One World Guideline for Aspergillosis.
Free to read: This content has been made available to all.